Frankfurt based Medigene last week acquired fellow Germans Trianta for the sum of €9.9 ($13.5). Trianta Immnotherapies, a Munich based start-up, develops novel cancer vaccines and development platforms, sepcialising in personalised T cell immunotherapy.
The move will see Medigene gaining 15 of the country’s top cancer vaccine researchers from the German Research Center for Environmental Health (Helmholtz Zentrum Munchen). Trianta evelved from the German Research Centre for Environmental Health back in 2013.
In a press release on the 27th of January 2014, Medigen said that Trianta was at ‘the forefront of personalized T cell immunotherapy.’ Medigene will now gain access to two vaccines currently under development by Trianta, who specialise in dendritic cell vaccines: a clinical phase I/II trial in acute myeloid leukemia (AML), and a clinical phase II trial in prostate cancer.
Along with the expertise of Trianta’s staff, including the notable researcher Professor Dolores Schendel, Medigene will have Triant’s three development platforms at their disposal: antigen-tailored dendritic cell (DC) vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs)
See the press release here.
connect with us on Google.